



May 6, 2022

Company name Shin Nippon Biomedical Laboratories, Ltd.  
Representative Ryoichi Nagata, MD, PhD,  
Representative Chairman, President & CEO  
Listing TSE PRIME section: ticker code 2395  
Inquiries Senior Officer & Senior Director,  
Corporate Communications, Toshiyuki Iwata  
TEL +81 3 5565 6216

### **Notice Regarding Differences between Actual Non-consolidated Financial Results for the Fiscal Year Ended March 31, 2022, and Those for the Previous Fiscal Year**

Shin Nippon Biomedical Laboratories, Ltd. (hereinafter, “the Company”) does not disclose projections of non-consolidated financial results. However, the Company hereby provides information regarding the differences between actual non-consolidated financial results for the fiscal year ended March 31, 2022 and those for the previous fiscal year, as detailed below.

#### **1. Differences between actual non-consolidated results for the fiscal year ended March 31, 2022 (April 1, 2021 to March 31, 2022) and those for the previous fiscal year**

	Revenue	Ordinary Profit	Profit	Profit per Share
	Million yen	Million yen	Million yen	JPY
Actual results for fiscal year ended March 31, 2021 (A)	13,541	2,760	2,858	68.67
Actual results for fiscal year ended March 31, 2022 (B)	16,570	6,330	5,247	126.04
Difference (B - A)	+3,028	+3,569	+2,388	
Difference (%)	+22.4	+129.3	+83.6	

#### **2. Reason of Differences**

In the actual non-consolidated results for the fiscal year ended March 31, 2022, revenue exceeded the results of the previous year mainly driven by a steady business performance of Company’s core operations, the CRO business. In addition, ordinary profit and profit further exceeded the results of the previous year due to an increase in foreign exchange gains led by the depreciation of the Japanese yen.